Evaluation of Intussusception After Oral Monovalent Rotavirus Vaccination in South Africa
- PMID: 31125061
- PMCID: PMC7146001
- DOI: 10.1093/cid/ciz431
Evaluation of Intussusception After Oral Monovalent Rotavirus Vaccination in South Africa
Abstract
Background: Postlicensure studies have shown an association between rotavirus vaccination and intussusception. We assessed the risk of intussusception associated with Rotarix (RV1) administration, at 6 and 14 weeks of age, in an upper-middle-income country, South Africa.
Methods: Active prospective surveillance for intussusception was conducted in 8 hospitals from September 2013 through December 2017. Retrospective case enrollment was done at 1 hospital from July 2012 through August 2013. Demographic characteristics, symptom onset, and rotavirus vaccine status were ascertained. Using the self-controlled case-series method, we estimated age-adjusted incidence rate ratios within 1-7, 8-21, and 1-21 days of rotavirus vaccination in children aged 28-275 days at onset of symptoms. In addition, age-matched controls were enrolled for a subset of cases (n = 169), and a secondary analysis was performed.
Results: Three hundred forty-six cases were included in the case-series analysis. Post-dose 1, there were zero intussusception cases within 1-7 days, and 5 cases within 8-21 days of vaccination. Post-dose 2, 15 cases occurred within 1-7 days, and 18 cases within 8-21 days of vaccination. There was no increased risk of intussusception 1-7 days after dose 1 (no cases observed) or dose 2 (relative incidence [RI], 1.71 [95% confidence interval {CI} .83-3.01]). Similarly, there was no increased risk 8-21 days after the first (RI, 4.01 [95% CI, .87-10.56]) or second dose (RI, .96 [95% CI, .52-1.60]). Results were similar for the case-control analysis.
Conclusions: The risk of intussusception in the 21 days after the first or second dose of RV1 was not higher than the background risk among South Africa infants.
Clinical trials registration: South African National Clinical Trial Register (DOH-27-0913-4183).
Keywords: infant; intussusception; rotavirus vaccine; safety.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures


Similar articles
-
Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation.Vaccine. 2023 Nov 22;41(48):7220-7225. doi: 10.1016/j.vaccine.2023.10.042. Epub 2023 Oct 24. Vaccine. 2023. PMID: 37884416 Free PMC article.
-
Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis.Vaccine. 2021 Jan 3;39(1):78-84. doi: 10.1016/j.vaccine.2020.09.019. Epub 2020 Sep 21. Vaccine. 2021. PMID: 32972735 Free PMC article.
-
Intussusception and Kawasaki disease after rotavirus vaccination in Taiwanese infants.Vaccine. 2020 Sep 11;38(40):6299-6303. doi: 10.1016/j.vaccine.2020.07.038. Epub 2020 Jul 28. Vaccine. 2020. PMID: 32736940
-
Intussusception following rotavirus vaccination: an updated review of the available evidence.Expert Rev Vaccines. 2014 Nov;13(11):1339-48. doi: 10.1586/14760584.2014.942223. Epub 2014 Jul 26. Expert Rev Vaccines. 2014. PMID: 25066368 Review.
-
Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines.Vaccine. 2015 Nov 27;33 Suppl 4:D55-9. doi: 10.1016/j.vaccine.2015.05.094. Epub 2015 Jun 27. Vaccine. 2015. PMID: 26122581 Review.
Cited by
-
Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation.Vaccine. 2023 Nov 22;41(48):7220-7225. doi: 10.1016/j.vaccine.2023.10.042. Epub 2023 Oct 24. Vaccine. 2023. PMID: 37884416 Free PMC article.
-
Epidemiology of intussusception in sub-Saharan Africa.Pan Afr Med J. 2021 Jul 27;39(Suppl 1):1. doi: 10.11604/pamj.supp.2021.39.1.30287. eCollection 2021. Pan Afr Med J. 2021. PMID: 34548893 Free PMC article.
-
Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.Vaccine. 2024 Mar 19;42(8):2059-2064. doi: 10.1016/j.vaccine.2024.02.057. Epub 2024 Feb 26. Vaccine. 2024. PMID: 38413278 Free PMC article.
-
Introducing ROTAVAC® to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition.Vaccine. 2023 Jan 23;41(4):945-954. doi: 10.1016/j.vaccine.2022.12.046. Epub 2022 Dec 28. Vaccine. 2023. PMID: 36585280 Free PMC article.
-
An overview of rotavirus vaccination programs in developing countries.Expert Rev Vaccines. 2020 Jun;19(6):529-537. doi: 10.1080/14760584.2020.1775079. Epub 2020 Jun 16. Expert Rev Vaccines. 2020. PMID: 32543239 Free PMC article. Review.
References
-
- Mpabalwani EM, Mwenda JM, Tate JE, Parashar UD. Review of naturally occurring intussusception in young children in the WHO African region prior to the era of rotavirus vaccine utilization in the expanded programme of immunization. J Trop Pediatr 2017; 63:221–8. - PubMed
-
- Murphy TV, Gargiullo PM, Massoudi MS, et al. . Rotavirus Intussusception Investigation Team Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564–72. - PubMed
-
- Vesikari T, Matson DO, Dennehy P, et al. . Rotavirus Efficacy and Safety Trial (REST) Study Team Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23–33. - PubMed
-
- Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. . Human Rotavirus Vaccine Study Group Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11–22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical